[Antitumor drug screening at the National Cancer Institute, U.S.A]
- PMID: 3310904
[Antitumor drug screening at the National Cancer Institute, U.S.A]
Abstract
The development of suitable screening systems is one of the most important determinants for the successful discovery of new anti-tumor drugs. The National Cancer Institute, U.S.A. has been playing a major role in the discovery and development of new agents by using various animal tumor models since 1955. In this article, the historical overview of this effort, and the difficulties and problems of this approach was reviewed. Also the new "Disease-Oriented Screening System", which is now under development as a new screening system at the National Cancer Institute was also described.
Similar articles
-
Anticancer drug development at the US National Cancer Institute.Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S29-33. doi: 10.1007/s00280-003-0623-y. Epub 2003 Jun 18. Cancer Chemother Pharmacol. 2003. PMID: 12819935
-
The role of the National Cancer Institute in drug development.Clin Adv Hematol Oncol. 2005 Apr;3(4):257-8. Clin Adv Hematol Oncol. 2005. PMID: 16166997 No abstract available.
-
Developing new agents for the treatment of childhood cancer.Curr Opin Investig Drugs. 2005 Dec;6(12):1215-27. Curr Opin Investig Drugs. 2005. PMID: 16372407 Review.
-
The preclinical new drug research program of the National Cancer Institute.Cancer Treat Rep. 1984 Jan;68(1):63-76. Cancer Treat Rep. 1984. PMID: 6692438
-
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.Bioorg Med Chem. 2012 Mar 15;20(6):1947-51. doi: 10.1016/j.bmc.2012.01.017. Epub 2012 Jan 21. Bioorg Med Chem. 2012. PMID: 22336246 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources